期刊
MULTIPLE SCLEROSIS JOURNAL
卷 22, 期 1, 页码 122-124出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458515597568
关键词
Adverse effects; case study; fingolimod; lymphoma; lymphomatoid papulosis; multiple sclerosis; risk factor; skin
Background: Fingolimod was the first oral disease-modifying treatment for relapsing-remitting multiple sclerosis. It has previously been associated with the development of lymphoma. Objective: To describe a case of lymphomatoid papulosis, a CD30+ cutaneous lymphoproliferative disorder, in a patient taking fingolimod. Methods: Case study. Results: Our patient developed lymphomatoid papulosis 2 months after starting fingolimod. Histology confirmed the diagnosis. The drug was withdrawn. Resolution began only 2 days later. Conclusions: Lymphomatoid papulosis is a benign subtype of cutaneous T-cell lymphoma, but up to 20% of cases can transform to a malignant course. Patients on fingolimod and physicians caring for them should be mindful of the need to monitor the skin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据